NIH Patents and Patent Applications

This list includes non-provisional and PCT patent filings.

CSV download of the complete patent data set.

For information on patent application codes, country codes, and patent status, see the Patents FAQ.

Tips:
Reset the Search Filters to go back to the initial display of all records.
Sort columns by clicking on the blue column headers.
The Search function searches across all columns.
To filter results by Lead IC, Country, or Application, type or use the dropdown menu.

Lead IC Reference Number Title Country Patent Application Type Application Number Date Filed Patent Number Date Issued Patent Status Patent PDF
NCI E-018-2017-0-IN-01 Graphene Oxide-Polycarbonate Track-Etched Nanosieve Platform For Sensitive Detection Of Human Immunodeficiency Virus Envelope Glycoprotein IN ORD 201711002764 Pending
NCI E-069-2016-0-CA-04 Therapeutic Antitumor Combination of a TLR4 Ligand With Other Treatments CA National Stage 3028654 Pending
NIAID E-294-2016-0-US-01 Compositions and Methods for Blocking Transmission of Plasmodium US 62/463,011 Abandoned
NLM E-107-2010-2-US-12 SELECTIVE OXIDATION OF 5-METHYLCYTOSINE BY TET -FAMILY PROTEINS US CON 15/440,815 10323269 Issued PDF
NLM E-107-2010-2-US-10 SELECTIVE OXIDATION OF 5-METHYLCYTOSINE BY TET -FAMILY PROTEINS US CON 15/440,284 10031131 Issued PDF
NLM E-107-2010-2-US-07 DETECTION OF 5-HYDROXYMETHYLCYTOSINE BY GLYCOSYLATION US CON 15/440,408 9816986 Issued PDF
NLM E-107-2010-2-US-09 SELECTIVE OXIDATION OF 5-METHYLCYTOSINE BY TET -FAMILY PROTEINS US CON 15/440,822 Abandoned
NLM E-107-2010-2-US-11 SELECTIVE OXIDATION OF 5-METHYLCYTOSINE BY TET -FAMILY PROTEINS US CON 15/440,319 Abandoned
NLM E-107-2010-2-US-08 SELECTIVE OXIDATION OF 5-METHYLCYTOSINE BY TET -FAMILY PROTEINS US CON 15/440,424 Abandoned
NIAID E-076-2015-4-BR-04 METHODS AND COMPOSITIONS FOR INDUCING PROTECTIVE IMMUNITY AGAINST FILOVIRUS INFECTION BR National Stage 112017003891-9 Pending
NCI E-174-2011-0-JP-18 Pseudomonas Exotoxin A With Less Immunogenic T Cell And/Or B Cell Epitopes JP DIV 2017-031283 Issued
CC E-183-2016-0-US-01 MULTI-PARAMETRIC MRI OF THE PROSTATE US 62/462,256 Abandoned
NCATS E-043-2017-2-US-01 Pharmaceutical Compositions With Antiflaviviral Activity US 62/461,492 Abandoned
NCI E-750-2013-0-HK-10 Methods for Subtyping Lymphoma Types by Means of Expression Profiling HK National Stage 17101847.4 Issued
NIAID E-181-2016-1-US-01 ZIKA VIRUS VACCINES US 62/461,095 Abandoned
NICHD E-016-2013-2-US-05 Assay To Measure Midkine or Pleiotrophin Level for Diagnosing a Growth US DIV 15/435,880 9658233 Issued PDF
NCI E-298-2016-0-US-01 Efficient Cell Free Production Of Papillomavirus Gene Transfer Vectors US 62/460,640 Abandoned
NCI E-291-2014-0-KR-08 Method For Purifying Antibody Using PBS KR National Stage 10-2017-7004441 Pending
NCATS E-009-2017-0-US-01 Inhibitors Of P53-S100B and Methods of Using the Same US 62/459,830 Abandoned
NCI E-062-2019-2-US-01 Method Of Treating Urothelial And Other Genitourinary Carcinomas Using N-(4-(6,7-dimethoxyquinolin-4-yloxy)phenyl)-N’-(4-fluorophenyl)cyclopropane-1,1-dicarboxamide, (2S)-hydroxybutanedioate US 62/459,340 Abandoned
CC E-136-2016-1-US-01 IMAGEABLE PARTICLES, METHODS OF MAKING AND METHODS OF USE THEREOF US 62/459,242 Abandoned
NCI E-136-2018-1-PL-24 Intermittent Dosing Of Cediranib Alone Or In Combination With Durvalumab PL EP 17753704.0 Issued
NCI E-136-2018-1-NO-23 Intermittent Dosing Of Cediranib Alone Or In Combination With Durvalumab NO EP 17753704.0 Issued
NCI E-136-2018-1-SE-25 Intermittent Dosing Of Cediranib Alone Or In Combination With Durvalumab SE EP 17753704.0 Issued
NCI E-136-2018-1-BE-13 Intermittent Dosing Of Cediranib Alone Or In Combination With Durvalumab BE EP 17753704.0 Issued
NCI E-136-2018-1-AT-12 Intermittent Dosing Of Cediranib Alone Or In Combination With Durvalumab AT EP 17753704.0 Issued
NCI E-136-2018-1-DE-16 Intermittent Dosing Of Cediranib Alone Or In Combination With Durvalumab DE EP 17753704.0 Issued
NCI E-136-2018-1-IT-21 Intermittent Dosing Of Cediranib Alone Or In Combination With Durvalumab IT EP 17753704.0 Issued
NCI E-136-2018-1-GR-18 Intermittent Dosing Of Cediranib Alone Or In Combination With Durvalumab GR EP 17753704.0 Issued
NCI E-136-2018-1-IE-20 Intermittent Dosing Of Cediranib Alone Or In Combination With Durvalumab IE EP 17753704.0 Issued
NCI E-136-2018-1-HU-19 Intermittent Dosing Of Cediranib Alone Or In Combination With Durvalumab HU EP 17753704.0 Issued
NCI E-136-2018-1-EP-05 Intermittent Dosing Of Cediranib Alone Or In Combination With Durvalumab EP National Stage 17753704.0 Issued
NCI E-136-2018-1-CZ-15 Intermittent Dosing Of Cediranib Alone Or In Combination With Durvalumab CZ EP 17753704.0 Issued
NCI E-136-2018-1-DK-17 Intermittent Dosing Of Cediranib Alone Or In Combination With Durvalumab DK EP 17753704.0 Issued
NCI E-136-2018-1-MA-08 Intermittent Dosing Of Cediranib Alone Or In Combination With Durvalumab MA EP 17753704.0 Issued
NCI E-136-2018-1-NL-22 Intermittent Dosing Of Cediranib Alone Or In Combination With Durvalumab NL EP 17753704.0 Issued
NCI E-136-2018-1-CH-14 Intermittent Dosing Of Cediranib Alone Or In Combination With Durvalumab CH EP 17753704.0 Issued
NCI E-136-2018-1-TR-26 Intermittent Dosing Of Cediranib Alone Or In Combination With Durvalumab TR EP 17753704.0 Issued
NCI E-136-2018-1-PCT-01 Intermittent Dosing Of Cediranib Alone Or In Combination With Durvalumab PCT PCT PCT/US2017/017804 Expired
NCI E-136-2018-1-AU-02 Intermittent Dosing Of Cediranib Alone Or In Combination With Durvalumab AU National Stage 2017221268 Pending
NCI E-063-2017-0-US-01 DENOISING OF DYNAMIC RESONANCE SPECTROSCOPIC IMAGING USING LOW RANK APPROXIMATIONS IN THE KINETIC DOMAIN US 62/459,008 Abandoned
NCI E-136-2018-1-RU-10 Intermittent Dosing Of Cediranib Alone Or In Combination With Durvalumab RU National Stage 2018131377 Pending
NCI E-136-2018-1-KR-07 Intermittent Dosing Of Cediranib Alone Or In Combination With Durvalumab KR National Stage 2018-7024215 Pending
NCI E-136-2018-1-MX-09 Intermittent Dosing Of Cediranib Alone Or In Combination With Durvalumab MX National Stage 2018009867 Pending
NCI E-136-2018-1-JP-06 Intermittent Dosing Of Cediranib Alone Or In Combination With Durvalumab JP National Stage 2021-064539 Pending
NCI E-136-2018-1-CA-03 Intermittent Dosing Of Cediranib Alone Or In Combination With Durvalumab CA National Stage 3014674 Pending
NCI E-136-2018-1-CN-04 Intermittent Dosing Of Cediranib Alone Or In Combination With Durvalumab CN National Stage 201780011505 Pending
NCI E-078-2016-0-PCT-02 RNA/DNA HYBRID NANOPARTICLES MODIFIED WITH SINGLE STRANDED RNA TOEHOLDS AND USES THEREOF PCT PCT PCT/US2017/017661 Expired
NCI E-062-2019-1-US-01 Method Of Treating Urothelial And Other Genitourinary Carcinomas Using N-(4-(6,7-dimethoxyquinolin-4-yloxy)phenyl)-N’-(4-fluorophenyl)cyclopropane-1,1-dicarboxamide, (2S)-hydroxybutanedioate US 62/457,952 Abandoned
NHLBI E-249-2006-3-PCT-02 Transcatheter Coronary Sinus Mitral Valve Annuloplasty Procedure And Coronary Artery And Myocardial Protection Device PCT PCT PCT/US2017/017367 Expired